Lineage Cell Therapeutics
LCTX
89 hedge funds and large institutions have $96.9M invested in Lineage Cell Therapeutics in 2020 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 18 increasing their positions, 15 reducing their positions, and 10 closing their positions.
1,983% more call options, than puts
Call options by funds: $1.44M | Put options by funds: $69K
140% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 10
93% more capital invested
Capital invested by funds: $50.2M → $96.9M (+$46.8M)
20% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 15
19% more funds holding
Funds holding: 75 → 89 (+14)
1% more ownership
Funds ownership: 35.72% → 36.72% (+1%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.37M |
| 2 |
ECM
ExodusPoint Capital Management
New York
|
+$1.11M |
| 3 |
Two Sigma Investments
New York
|
+$472K |
| 4 |
Two Sigma Advisers
New York
|
+$241K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$191K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$612K |
| 2 |
NFC
Northeast Financial Consultants
Westport,
Connecticut
|
-$491K |
| 3 |
DC
Defender Capital
Charlotte,
North Carolina
|
-$438K |
| 4 |
Jane Street
New York
|
-$214K |
| 5 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$86K |
LCTX Hedge Fund Activity: Q4 2020 in Review
89 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Lineage Cell Therapeutics (LCTX) for Q4 2020, worth a combined $96.9M — up 93% from $50.2M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new LCTX positions and 10 closed out — a net gain of 14 holders — while 18 added to existing stakes and 15 trimmed.
The largest buyer was Vanguard Group, adding an estimated $1.37M. The largest seller was Renaissance Technologies, cutting an estimated $612K.
- 89 institutional investors held Lineage Cell Therapeutics (LCTX) as of Q4 2020, up from 75 in Q3 2020.
- Funds reported $96.9M of Lineage Cell Therapeutics stock for Q4 2020, up 93% quarter-over-quarter.
- 24 funds opened new Lineage Cell Therapeutics positions in Q4 2020 and 10 closed out, a net change of +14 holders.
- The largest Lineage Cell Therapeutics buyer in Q4 2020 was Vanguard Group, an estimated $1.37M added.
- The largest Lineage Cell Therapeutics seller in Q4 2020 was Renaissance Technologies, an estimated $612K sold.
Based on aggregated 13F filings for Q4 2020.